Treprostinil
Q&A: Yutrepia for PAH, pulmonary hypertension-ILD receives tentative FDA approval
Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.
FDA has yet to confirm Yutrepia for pulmonary hypertension-ILD
The FDA did not meet its Prescription Drug User Fee Act goal date that would extend Yutrepia as a treatment for patients with pulmonary hypertension associated with interstitial lung disease, according to a press release.
Inhaled treprostinil safe, improves outcomes in pulmonary hypertension-ILD over 1 year
Inhaled treprostinil was safe in patients with pulmonary hypertension associated with interstitial lung disease over 1 year and sustained improved exercise capacity, according to study results published in European Respiratory Journal.
Q&A: Treating pulmonary hypertension-ILD with high-dose inhaled treprostinil
Inhaled treprostinil is used to treat pulmonary hypertension with interstitial lung disease, and a study recently found that higher doses led to better clinical outcomes than a lower dose or placebo.
Higher-dose treprostinil yields greater improvements in pulmonary hypertension-ILD
Patients with pulmonary hypertension associated with interstitial lung disease had better outcomes with a higher dose of inhaled treprostinil, as compared with a lower dose or placebo, according to a study.
Inhaled treprostinil improves persistence, lowers risk for PAH hospitalization vs. iloprost
SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for hospitalization compared with iloprost in patients with pulmonary arterial hypertension, researchers reported.
VIDEO: Updates in pulmonary hypertension highlighted at ATS 2022
SAN FRANCISCO — In this video exclusive, Belinda Natalia Rivera-Lebron, MD, MS, highlights recent updates in the treatment of pulmonary hypertension.
FDA approves inhaled treprostinil for treatment of PAH, pulmonary hypertension-ILD
United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
World PH Day spotlights the global impact of pulmonary hypertension
May 5 is World PH Day, which aims to raise awareness of pulmonary hypertension and its global impact.
Transition to dry powder inhaled treprostinil safe, tolerable for patients with PAH
Transition from nebulized inhaled treprostinil to a dry powder inhaled formulation was safe, well tolerated and led to significant improvements in clinical and patient-reported outcomes in patients with pulmonary arterial hypertension.